Canadian Court Blocks Generic Celebrex Launch

Law360, New York (May 1, 2007, 12:00 AM EDT) -- A Canadian appeals court has upheld patents for painkiller Celebrex that prevent the launch of a generic version of the drug until November 2014, Pfizer Inc. said Tuesday.

The Federal Court of Appeal of Canada reversed a lower court ruling that permitted Teva Pharmaceuticals’ Canadian subsidiary Novopharm from launching its version of Celebrex. The appellate court’s order prohibits regulatory approval of a generic Celebrex until Pfizer’s patents regarding the drug’s compound expire in 2014.

“Without appropriate protection of intellectual property, Pfizer and other research-based pharmaceutical companies...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.